- Home
- INO vs NKTR Comparison
INO vs NKTR Comparison
Compare INO & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INO
- NKTR
- Stock Information
- Founded
- INO 1979
- NKTR 1990
- Country
- INO United States
- NKTR United States
- Employees
- INO N/A
- NKTR N/A
- Industry
- INO Medical/Dental Instruments
- NKTR Biotechnology: Pharmaceutical Preparations
- Sector
- INO Health Care
- NKTR Health Care
- Exchange
- INO Nasdaq
- NKTR Nasdaq
- Market Cap
- INO 148.3M
- NKTR 238.7M
- IPO Year
- INO 1998
- NKTR 1994
- Fundamental
- Price
- INO $5.67
- NKTR $1.45
- Analyst Decision
- INO Buy
- NKTR Buy
- Analyst Count
- INO 6
- NKTR 4
- Target Price
- INO $21.17
- NKTR $2.50
- AVG Volume (30 Days)
- INO 380.1K
- NKTR 1.3M
- Earning Date
- INO 11-07-2024
- NKTR 11-05-2024
- Dividend Yield
- INO N/A
- NKTR N/A
- EPS Growth
- INO N/A
- NKTR N/A
- EPS
- INO N/A
- NKTR N/A
- Revenue
- INO $591,858.00
- NKTR $93,157,000.00
- Revenue This Year
- INO N/A
- NKTR N/A
- Revenue Next Year
- INO N/A
- NKTR N/A
- P/E Ratio
- INO N/A
- NKTR N/A
- Revenue Growth
- INO N/A
- NKTR 6.17
- 52 Week Low
- INO $3.84
- NKTR $0.41
- 52 Week High
- INO $14.75
- NKTR $1.93
- Technical
- Relative Strength Index (RSI)
- INO 41.86
- NKTR 63.84
- Support Level
- INO $5.44
- NKTR $1.27
- Resistance Level
- INO $5.77
- NKTR $1.39
- Average True Range (ATR)
- INO 0.27
- NKTR 0.09
- MACD
- INO 0.09
- NKTR 0.01
- Stochastic Oscillator
- INO 50.68
- NKTR 88.89
About INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.